01—Abstract
Summary
Summary of the 8-K filed November 19, 2021. Cited figures are marked; the original filing is the authoritative source.
Agilent Technologies, Inc. (A) announced a strategic expansion of its Board of Directors through the appointment of Dr. Otis W.
Brawley, effective November 17, 2021. Dr. Brawley's addition increases the Board size from 11 to 12 members and brings a wealth of experience in oncology, epidemiology, and public health, with prior roles at Johns Hopkins University and the American Cancer Society.
His appointment is expected to enhance the Board's expertise, particularly within the healthcare and life sciences sectors, aligning with Agilent's focus. He will serve on both the Compensation and Nominating/Corporate Governance Committees and will receive standard non-employee director compensation.
02—Key points
Key Highlights
- Agilent Technologies appointed Dr. Otis W. Brawley to its Board of Directors, increasing the Board size to 12 members.
- Dr. Brawley brings extensive expertise in oncology, epidemiology, and public health, holding a professorship at Johns Hopkins University and formerly serving as Chief Medical and Scientific Officer at the American Cancer Society.
- His appointment is effective November 17, 2021, and he will serve on the Compensation Committee and the Nominating/Corporate Governance Committee.
- Dr. Brawley has been determined to meet NYSE independence standards and has no disqualifying arrangements or family relationships with existing directors or officers.
- He has no prior material interest in any transactions with Agilent and currently holds no beneficial ownership of the company's stock.
- Dr. Brawley will receive standard compensation for non-employee directors, pro-rated for his tenure in the current year.
- The company issued a press release on November 18, 2021, to announce this board appointment.
03—Questions
Frequently Asked Questions
Who is Dr. Otis W. Brawley and what is his background?
Dr. Otis W. Brawley is a distinguished medical professional with extensive experience in oncology and epidemiology. He currently serves as a Bloomberg Distinguished Professor of Oncology and Epidemiology at Johns Hopkins University. Previously, he was the Chief Medical and Scientific Officer at the American Cancer Society from 2007 to 2018. He also has experience as an Internist, Oncologist, and Professor at Emory University.
Why has Agilent appointed Dr. Brawley to its Board?
Dr. Brawley's appointment, effective November 17, 2021, increases the Board's size to 12 members and is intended to leverage his significant expertise in healthcare and life sciences, particularly in oncology and epidemiology. He will serve on key committees, including the Compensation Committee and the Nominating/Corporate Governance Committee, contributing to strategic oversight and governance.
Does Dr. Brawley have any conflicts of interest or prior ties to Agilent?
The filing indicates that Dr. Brawley meets the independence standards required by the NYSE and has no undisclosed arrangements or understandings related to his appointment. He has had no direct or indirect material interest in any transactions with Agilent and currently holds no beneficial ownership of the company's stock. He is currently serving on the boards of other biotechnology companies like Incyte Corporation, Lyell Immunopharma, Inc., and PDS Biotechnology Corp.
How will Dr. Brawley be compensated for his role on the Board?
Dr. Brawley will receive the standard compensation provided to Agilent's non-employee directors. This compensation will be pro-rated to reflect the actual time he serves on the Board during the current year. Further details on non-employee director compensation are available in Agilent's proxy statement filed on February 4, 2021.
04—Continue